Risultati per: L’eparina inibisce la proteina spike del virus SARS-Cov-2

Winkler NE, Koirala A, Kaur G, et al. Seroprevalence of Japanese encephalitis virusspecific antibodies in Australia following novel epidemic spread: protocol for a national crosssectional study. BMJ Open 2024;14:e075569. doi:10.1136/ bmjopen-2023-075569 This article has been corrected since it was published online. The changes clarify statements that were unclear on the status of and requirements for ethical approvals. The changes made are mentioned below. EthicsNational Mutual Acceptance ethical approval was obtained from the Sydney Children’s Hospitals Network Human Research Ethics Committee (HREC). Local approvals were planned to be sought in each jurisdiction, as per local ethics processes. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC. Active collections are proposed for populations with geographical distribution mirroring locations of human, animal and vector detections in the Northern Territory, Queensland, New South Wales, Victoria, South Australia and Western Australia, (table 1,figure 1B) subject to local…

Per bambini nati da aprile 2024. Nel 2023 furono 800 i ricoveri

Meno malattie dell’invecchiamento e nei topo la vita sana si allunga del 25%

L’infezione provoca febbre molto alta, dolori articolari e muscolari e rash cutaneo e si trasmette attraverso le punture di moscerini o di zanzare

New England Journal of Medicine, Volume 391, Issue 3, Page 283-285, July 18, 2024.

New England Journal of Medicine, Volume 391, Issue 3, Page 285-287, July 18, 2024.

New England Journal of Medicine, Ahead of Print.

Researchers have confirmed two specific variations in immune response that might lead to preventive and treatment interventions for COVID-19.

Objectives
Studies have reported high incidences of stroke in patients hospitalised with SARS-CoV-2, but the impact of disease severity is unexplored. We aimed to estimate the risk of incident ischaemic stroke in SARS-CoV-2 test-positive individuals compared with test-negative individuals stratified by disease severity during acute infection and post infection.

Design
A register-based cohort study.

Setting
A Danish nationwide study.

Participants
All Danish adults who had PCR tests for SARS-CoV-2 performed between 1 March 2020 and 30 November 2021. Test-positive individuals were included at their first positive test. For individuals tested prior to 30 November 2021, we randomly sampled an index date from the distribution of test dates among SARS-CoV-2 test-positive individuals. Test-positive individuals were followed during the acute phase of infection (days 0–14) and post infection (180 days after the acute phase). Test-negative individuals were followed in equivalent time periods.

Primary and secondary outcome measures
Incident ischaemic stroke risk in SARS-CoV-2 test-positive individuals compared with test-negative individuals during acute infection and post infection. We calculated subdistribution HRs (SHR) with death as a competing risk using propensity score weighting as confounder control. The risk was stratified according to disease severity: community managed, hospitalised, or admission to the intensive care unit.

Results
Among 3 910 219 SARS-CoV-2 PRC-tested individuals, 356 421 test-positive and 3 067 456 test-negative individuals were included. A positive SARS-CoV-2 test was associated with an SHR of 3.32 (95% CI 2.60 to 4.25) overall for stroke compared with test negative in the acute phase. In the postinfection period, the risk of stroke remained increased in individuals hospitalised during the acute phase (SHR 1.85, 95% CI 1.45 to 2.37). Individuals with community-managed SARS-CoV-2 had no increased long-term risk of stroke (SHR 1.01, 95% CI 0.88 to 1.16).

Conclusion
SARS-CoV-2 infection is associated with increased stroke risk. Disease severity seems to be an important factor. Individuals with community-managed SARS-CoV-2 had no increased stroke risk.

Annals of Internal Medicine, Ahead of Print.

Individuals with a previous infection with Zika virus may be more vulnerable to symptomatic infections of certain types of dengue virus, according to a cohort study of 3412 children aged 2 to 17 years old in Nicaragua.

The recent publication by Ng et al titled ‘Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events’ provides valuable insights on gut microbiota in modulating immune responses to both inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccines. The authors identified specific gut microbiota markers influenced immunity and vaccine efficacy, suggesting that microbiota-targeted interventions could potentially enhance vaccine effectiveness in adults.1 Expanding on Ng et al’s research, our study further investigates the associations between gut microbial taxa, metabolites and immune response to inactivated vaccines. Our findings establish a connection between maternal gut microbiota/metabolites and the efficacy of mother-to-infant antibody transfer, providing a potential protective strategy for infants against COVID-19 symptoms. We conducted a prospective, observational investigation involving 97 vaccinated pregnant women in Guangdong, China, and profiled gut microbiota and metabolome using shotgun metagenomics and non-targeted metabolomics. All participants received two doses of inactivated SARS-CoV-2 vaccine, including…

Objective
In order to predict at hospital admission the prognosis of patients with serious and life-threatening COVID-19 pneumonia, we sought to understand the clinical characteristics of hospitalised patients at admission as the SARS-CoV-2 pandemic progressed, document their changing response to the virus and its variants over time, and identify factors most importantly associated with mortality after hospital admission.

Design
Observational study using a prospective hospital systemwide COVID-19 database.

Setting
15-hospital US health system.

Participants
26 872 patients admitted with COVID-19 to our Northeast Ohio and Florida hospitals from 1 March 2020 to 1 June 2022.

Main outcome measures
60-day mortality (highest risk period) after hospital admission analysed by random survival forests machine learning using demographics, medical history, and COVID-19 vaccination status, and viral variant, symptoms, and routine laboratory test results obtained at hospital admission.

Results
Hospital mortality fell from 11% in March 2020 to 3.7% in March 2022, a 66% decrease (p

Objective
To assess healthcare workers’ (HCWs) confidence level in diagnosing and managing mpox disease and its associated factors in hospitals in the Amhara Region.

Design
Institution-based cross-sectional study.

Setting
Hospitals in the Amhara Region, Northwest Ethiopia.

Participants
A total of 640 HCWs, with a response rate of 96.9%, participated from 1 October to 30 December 2022. A multistage stratified random sampling technique with proportional allocation was used to recruit study participants. Data were collected using the KoboCollect toolbox and exported to STATA V.17 for analysis. Descriptive statistics were used to describe data. Ordinal logistic regression analysis was used to identify predictors of confidence level to diagnose and manage mpox at p

This JAMA Insights discusses the use of monoclonal antibodies or protein-based vaccines to help prevent severe RSV infection in infants, children, and older adults.

New England Journal of Medicine, Ahead of Print.